Boditech Med Signs MOU with China’s Autobio for Joint Development and Sales Collaboration

• Comprehensive partnership established to jointly develop core products and expand sales.

• Strategic collaboration to diversify diagnostic portfolios across multiple fields.

Boditech Med, a leader in point-of-care diagnostics, announced on the 15th that it has signed a Memorandum of Understanding (MOU) with Autobio Diagnostics Co., Ltd., one of China’s top five in vitro diagnostics (IVD) companies, to jointly develop and expand sales of key products.

Autobio is known for its strengths in large-scale diagnostic equipment systems, including blood testing, biochemistry, and immunology. The company has established a robust domestic market foundation in China, securing stable revenue growth and profitability. In recent years, Autobio has also accelerated its efforts to enter overseas markets.

The agreement aims to establish a comprehensive collaboration framework focused on joint development and sales of core products. Boditech Med, a leading global company with a network supplying point-of-care diagnostic systems to over 130 countries, is expected to help Autobio strengthen its presence in international markets, including South Korea.

Boditech Med selected Autobio as a strategic partner to leverage its expertise in immunodiagnostics and expand its product portfolio into diverse diagnostic fields such as biochemistry and microbiology. The two companies plan to jointly conduct research and development and collaborate to broaden their range of diagnostic products, driving market expansion.

Eui-yeol Choi, CEO of Boditech Med, stated, “This agreement will serve as a crucial milestone for both companies to generate synergies in the global diagnostics market by combining our technological capabilities and networks.”